Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26355047 | 0.84 | KIF11 (0.32) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL26355050 | 0.80 | KIF11 (0.30) | KIF11 | |
| SCHEMBL26355004 | 0.76 | KIF11 (0.40) | KIF11SLC6A1SLC6A11KCNH2CHRM3 | |
| SCHEMBL26355009 | 0.74 | — | — | |
| SCHEMBL26355029 | 0.74 | — | — | |
| SCHEMBL16144257 | 0.70 | KIF11 (0.35) | KIF11SLC6A1SLC6A11KCNH2LMNA | |
| SCHEMBL23560968 | 0.70 | SLC6A11 (0.39) | KIF11SLC6A1SLC6A11KCNH2CHRM3 | |
| SCHEMBL6406915 | 0.70 | EDNRA (0.43) | KIF11SLC6A1SLC6A11KCNH2SMN1; SMN2 | |
| SCHEMBL25765939 | 0.66 | KIF11 (0.49) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL1259992 | 0.65 | KIF11 (0.39) | KIF11SLC6A1SLC6A11KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | KIF11 3084/4885SLC6A1 3014/4885SLC6A11 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.